Welcome to our dedicated page for Lexaria Bioscience SEC filings (Ticker: LEXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexaria Bioscience Corp. filings document a Nevada biotechnology company developing and licensing DehydraTECH, its oral drug delivery platform. Registration statements and periodic disclosure materials describe the company's intellectual property licensing segment, research and development activities, B2B initiatives, common stock, warrants, stock options, and risk factors tied to its technology and commercialization model.
Lexaria's 8-K filings record material financing and capital-structure events, including securities purchase agreements, registered direct offerings, concurrent private placement warrants, and the termination of an at-the-market sales agreement. Other filings cover annual meeting voting results, auditor appointment, Nasdaq listing-compliance notices for common stock, and Form 25 records involving warrant listing and registration status.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company focused on improving oral delivery of drugs using its patented DehydraTECH technology, which combines active pharmaceutical ingredients with long-chain fatty acids to boost bioavailability and tolerability. The platform targets GLP‑1/GIP drugs, CBD, nicotine, antivirals and other molecules across indications such as diabetes, obesity, hypertension, epilepsy and heart disease, and can be used in multiple oral dosage forms.
The company reports an extensive intellectual property portfolio with 56 granted patents worldwide across several families, including recent protections for GLP‑1/GIP diabetes and obesity treatments, epilepsy, diabetes, nicotine and food applications. Lexaria spent $8.2 million on R&D in fiscal 2025, advancing multiple human and animal studies of DehydraTECH-enhanced GLP‑1/GIP drugs and CBD, and has an FDA-cleared IND and 505(b)(2) pathway for a Phase 1b hypertension trial using DehydraTECH‑CBD.
At August 31, 2025, Lexaria had $1.8 million in unrestricted cash and cash equivalents versus $1.5 million in current liabilities and disclosed substantial doubt about its ability to continue as a going concern without additional financing, partnerships or cost reductions. As of November 25, 2025, there were 22,225,846 common shares outstanding, and the non‑affiliate equity market value at the prior second quarter date was about $24.6 million.
Lexaria Bioscience Corp. filed a Form S-1 registering for resale up to 2,760,000 shares of common stock issuable upon exercise of outstanding warrants from the September 2025 Offering and an engagement with H.C. Wainwright & Co. The company is not selling any shares in this offering and will not receive proceeds from any resale by the selling stockholders. If the warrants are exercised for cash, Lexaria would receive approximately $3,828,333.
Common stock outstanding was 22,225,846 shares as of October 9, 2025, and would be 24,985,846 shares assuming exercise of all registered warrants. The prospectus outlines standard methods of sale by selling stockholders and notes Nasdaq listings under “LEXX” and “LEXXW.” Risk factors include potential price pressure from resales and dilution from warrant exercises, and a going‑concern note citing $4.6 million in cash and cash equivalents against $1.5 million in current liabilities as of May 31, 2025.
Lexaria Bioscience Corp. filed a Form D reporting a completed Regulation D offering under Rule 506(b) for total proceeds of $4,000,000. The filing states the entire offering amount was sold and no remaining securities are available. The offering included registered shares combined with unregistered warrants and a 7% sales commission paid, totaling an estimated $280,000.
The issuer lists its principal place of business in Kelowna, British Columbia, and identifies multiple executives and directors at that address. The offering involved 5 investors, was not connected to any business combination, had a minimum outside investment of $0, and used H.C. Wainwright & Co. as the associated broker-dealer. No proceeds were allocated to payments to named officers, directors, or promoters per the filing.
Lexaria Bioscience Corp. entered into a securities purchase agreement with institutional investors, issuing 2,666,667 shares of common stock in a registered direct offering at $1.50 per share and, in a concurrent private placement, 2,666,667 warrants exercisable at $1.37 per share. The transaction, which closed on September 29, 2025, generated approximately $4.0 million in gross proceeds that the company plans to use for working capital and general corporate purposes.
The private placement warrants are immediately exercisable for five years from the effectiveness of a resale registration statement and include a beneficial ownership cap of 4.99%, which holders may increase up to 9.99% with notice. Lexaria agreed to file a resale registration statement for the warrant shares shortly after signing and to keep it effective until the investors no longer hold these securities.
H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee on gross proceeds and 93,333 warrants with a $1.875 exercise price, plus specified expense reimbursements. The company also agreed to a 60-day restriction on most additional equity issuances and related registration filings, with limited exceptions.
Lexaria reports clinical study signals for its DehydraTECH oral delivery platform showing several enhanced formulations outperformed the oral GLP-1 control Rybelsus® on 12-week body weight control and body-weight improvement, with statistically significant advantages by week 12 for most enhanced arms. Specific arms showed blood sugar changes: DehydraTECH-liraglutide (Group H) -11.540%, and select DehydraTECH-CBD arms Group A 1.09% and Group B -3.76%. Pharmacokinetic results for DehydraTECH-tirzepatide showed fewer adverse events than injected Zepbound®, lower but steadier blood levels that reached parity with Zepbound by study end. The study reached last patient last visit on August 14, 2025, enabling full sample and data analyses toward a late-2025 final report. DehydraTECH is described as a drug-delivery platform combining APIs with long-chain fatty acid-rich triglyceride oils and carriers to improve oral absorption and tolerability.
Lexaria Bioscience Corp. terminated its Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC effective September 19, 2025. This agreement had allowed the company to issue and sell, from time to time, up to $5,000,000 of its common stock through or to JonesTrading as sales agent or principal.
By the time of termination, Lexaria had sold only 14,995 shares under the program, generating $38,236 in gross proceeds. With the agreement now ended, the company no longer has this specific at-the-market equity facility available for future common stock sales.